neflamapimod

Small molecule

Negativelead readout

Evidence outlook · lead readout

RewinD-LB (NCT05869669) · Dementia With Lewy Bodies

The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.

RewinD-LB (NCT05869669): The blinded treatment period was randomized, quadruple-masked, placebo-controlled, and included 159 participants (79 assigned to neflamapimod and 80 to placebo). Its clinical primary endpoint was not met: the difference in CDR-SB change was 0.01 points, with p=0.9448.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 2 (10)
Dementia with Lewy Bodies
NCT06815965 · EIP Pharma Inc
2024-10-16 – 2026-03-25 · Dementia With Lewy Bodies (DLB)
What this study did
NCT04001517 · EIP Pharma Inc
2019-09-30 – 2020-06-30 · Dementia With Lewy Bodies (DLB)
What this study did
Other / comorbidity
NCT06987643 · EIP Pharma Inc
2025-06-20 – 2026-10-06 · Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke
What this study did
NCT07033481 · EIP Pharma Inc
2025-10-02 – 2026-10 · Nonfluent Variant Primary Progressive Aphasia (nfvPPA)
What this study did
NCT03435861 · University Hospital, Toulouse
2018-10-08 – 2021-06-30 · Alzheimer Disease
What this study did
NCT03980938 · EIP Pharma Inc
2019-07-08 – 2020-10-15 · Huntington Disease
What this study did
NCT03402659 · EIP Pharma Inc
2017-12-29 – 2019-07-31 · Alzheimer Disease
What this study did
NCT02423200 · EIP Pharma Inc
2015-04 – 2016-11 · Alzheimer's Disease
What this study did
NCT02423122 · EIP Pharma Inc
2015-04 – 2016-09 · Alzheimer's Disease, Mild Cognitive Impairment
What this study did

Competitive landscape

This drug's own stage for Dementia with Lewy Bodies: Phase 2. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Neflamapimod: this drugPhase 2Small moleculep38-alpha MAPKPartial signal
NCT05869669: Change in Clinical Dementia Rating Scale - Sum of Boxes (CDR-SB) in Neflamapimod-treated Participants Compared to Placebo Recipients (Blinded Treatment Period) (16 weeks): Neflamapimod 0.36 Scores on a scale (Standard Error 0.193) | Placebo 0.34 Scores on a scale (Standard Error 0.188) missed
ZervimesinePhase 2Small moleculeSigma-2 receptor complexnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.